{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:43:28Z","timestamp":1758818608052,"version":"3.37.0"},"reference-count":25,"publisher":"Wiley","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2495,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1111\/j.1529-8019.2008.00235.x","type":"journal-article","created":{"date-parts":[[2008,12,10]],"date-time":"2008-12-10T00:24:30Z","timestamp":1228868670000},"page":"S6-S14","source":"Crossref","is-referenced-by-count":5,"special_numbering":"supplement","title":["Long-term efficacy of up to 15 months\u2019 efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis"],"prefix":"10.1155","volume":"21","author":[{"given":"Darryl P.","family":"Toth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Papp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Gratton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"issue":"Suppl. 2","key":"10.1111\/j.1529-8019.2008.00235.x-BIB1","doi-asserted-by":"crossref","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","article-title":"Psoriasis: epidemiology, clinical features, and quality of life","volume":"64","author":"Langley","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1529-8019.2008.00235.x-BIB2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000092283","article-title":"Epidemiology of psoriasis. Review and the German perspective","volume":"212","author":"Schafer","year":"2006","journal-title":"Dermatology"},{"key":"10.1111\/j.1529-8019.2008.00235.x-BIB3","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2133.2005.06893.x","article-title":"British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005","volume":"153","author":"Smith","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00235.x-BIB4","first-page":"1","article-title":"A systematic review of treatments for severe psoriasis","volume":"4","author":"Griffiths","year":"2000","journal-title":"Health Technol Assess Rep"},{"key":"10.1111\/j.1529-8019.2008.00235.x-BIB5","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1067\/mjd.2001.117047","article-title":"Treatment of psoriasis. Part 2. Systemic therapies","volume":"45","author":"Lebwohl","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00235.x-BIB6","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1067\/mjd.2001.117046","article-title":"Treatment of psoriasis. Part 1. Topical therapy and phototherapy","volume":"45","author":"Lebwohl","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00235.x-BIB7","first-page":"352","article-title":"Psoriasis from the patient's point of view","volume":"137","author":"Finlay","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00235.x-BIB8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/00002018-200629010-00004","article-title":"Fulfilling an unmet need in psoriasis: do biologicals hold the key to improved tolerability?","volume":"29","author":"Shear","year":"2006","journal-title":"Drug Saf"},{"key":"10.1111\/j.1529-8019.2008.00235.x-BIB9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1159\/000077660","article-title":"T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action","volume":"208","author":"Jullien","year":"2004","journal-title":"Dermatology"},{"key":"10.1111\/j.1529-8019.2008.00235.x-BIB10","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.4049\/jimmunol.157.11.4986","article-title":"Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1","volume":"157","author":"Werther","year":"1996","journal-title":"J Immunol"},{"key":"10.1111\/j.1529-8019.2008.00235.x-BIB11","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1001\/jama.290.23.3073","article-title":"Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial","volume":"290","author":"Gordon","year":"2003","journal-title":"JAMA"},{"key":"10.1111\/j.1529-8019.2008.00235.x-BIB12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/archderm.141.1.31","article-title":"Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis","volume":"141","author":"Menter","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00235.x-BIB13","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMoa030002","article-title":"A novel targeted T-cell modulator, efalizumab, for plaque psoriasis","volume":"349","author":"Lebwohl","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1529-8019.2008.00235.x-BIB14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jaad.2004.09.029","article-title":"Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial","volume":"52","author":"Leonardi","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00235.x-BIB15","first-page":"614","article-title":"Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis","volume":"3","author":"Gottlieb","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00235.x-BIB16","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/j.jaad.2005.12.018","article-title":"Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial","volume":"54","author":"Gottlieb","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00235.x-BIB17","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/j.1365-2133.2008.08548.x","article-title":"Efalizumab: results of a three-year continuous dosing study for the long-term control of psoriasis","volume":"158","author":"Leonardi","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00235.x-BIB18","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2133.2006.07344.x","article-title":"Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial","volume":"155","author":"Dubertret","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00235.x-BIB19","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1610-0387.2006.06111.x","article-title":"Clinical experience acquired with Raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from extended treatment in an international, phase III, placebo-controlled trial","volume":"4","author":"Sterry","year":"2006","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1111\/j.1529-8019.2008.00235.x-BIB20","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-4632.2006.02777.x","article-title":"Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial","volume":"45","author":"Papp","year":"2006","journal-title":"Int J Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00235.x-BIB21","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2165\/00002018-200831080-00008","article-title":"Safety of efalizumab therapy in an open-label extension of a phase IIIb trial of patients with moderate to severe psoriasis","volume":"31","author":"Hamilton","year":"2008","journal-title":"Drug Saf"},{"key":"10.1111\/j.1529-8019.2008.00235.x-BIB22","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1046\/j.1087-0024.2003.09110.x","article-title":"Quality of life in patients with psoriasis: a systematic literature review","volume":"9","author":"de Korte","year":"2004","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1111\/j.1529-8019.2008.00235.x-BIB23","first-page":"280","article-title":"The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey","volume":"137","author":"Krueger","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00235.x-BIB24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","article-title":"Psoriasis causes as much disability as other major medical diseases","volume":"41","author":"Rapp","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2008.00235.x-BIB25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-5945-5-13","article-title":"Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled phase III clinical experience acquired with Raptiva (CLEAR) trial [NCT00256139]","volume":"5","author":"Ortonne","year":"2005","journal-title":"BMC Dermatol"}],"container-title":["Dermatologic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1529-8019.2008.00235.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1529-8019.2008.00235.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T03:15:43Z","timestamp":1738811743000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1529-8019.2008.00235.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":25,"URL":"https:\/\/doi.org\/10.1111\/j.1529-8019.2008.00235.x","relation":{},"ISSN":["1396-0296","1529-8019"],"issn-type":[{"type":"print","value":"1396-0296"},{"type":"electronic","value":"1529-8019"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}